Percutaneous balloon aortic valvuloplasty: Antegrade transseptal vs. conventional retrograde transarterial approach

Percutaneous balloon aortic valvuloplasty (BAV) has been limited predominantly to a palliative treatment for poor surgical candidates with critical aortic stenosis and multiple high‐risk or comorbid conditions. The most commonly used technique for BAV is the retrograde approach, in which the balloon...

Full description

Saved in:
Bibliographic Details
Published inCatheterization and cardiovascular interventions Vol. 64; no. 3; pp. 314 - 321
Main Authors Sakata, Yoshihito, Syed, Zubair, Salinger, Michael H., Feldman, Ted
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.03.2005
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Percutaneous balloon aortic valvuloplasty (BAV) has been limited predominantly to a palliative treatment for poor surgical candidates with critical aortic stenosis and multiple high‐risk or comorbid conditions. The most commonly used technique for BAV is the retrograde approach, in which the balloon is passed via the femoral artery using 12–14 Fr sheaths. We compared an antegrade transseptal approach using the Inoue balloon vs. the retrograde transarterial approach using conventional balloons. The antegrade group had an improved acute hemodynamic outcome, including 20% additional increase of aortic valve area and 20% greater reduction of transaortic valve gradient compared to the retrograde approach. Preclosure with the Perclose device was used for the 14 Fr venous access sites, resulting in immediate hemostasis, minimizing the need for transfusion, and diminishing the period of bed rest. The improved acute efficacy and relative ease of venous access for the antegrade approach facilitate BAV by eliminating the need for large‐caliber arterial access sheaths. The antegrade approach also incorporates technical elements necessary for percutaneous aortic valve replacement and may have expanded applications as an adjunct to this developing therapy. The impact of improved acute results on the long‐term clinical outcome for this patient group will require further study. Catheter Cardiovasc Interv 2005;64:314–321. © 2005 Wiley‐Liss, Inc.
Bibliography:istex:6CE5F6CD1B801099201B1593EC5D6AD6F8B04384
ArticleID:CCD20300
ark:/67375/WNG-H74SN03W-0
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1522-1946
1522-726X
DOI:10.1002/ccd.20300